BMY - Bristol-Myers Squibb • Financials

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2016	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	45,006	17,042	-	18%	3.9	29,430	27%	27,492	1.6	13,342	-1,209	-9,416	12,133	-5,155	-4,744	59%	4.5%
12/2024	48,300	2,114	-	L	L	16,335	L	38,790	18	14,683	-1,248	5,127	13,435	0	-4,863	L	4.2%
12/2025	48,194	14,013	-	15%	3.5	18,473	38%	34,438	2.5	13,603	-1,311	-10,348	12,292	0	-5,045	72%	4.6%

To see all financials—including updated, you must be Premium.